Compare EOI & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Current Price
| Metric | EOI | NUVB |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 805.7M | 2.9B |
| IPO Year | N/A | N/A |
| Metric | EOI | NUVB |
|---|---|---|
| Price | $20.74 | $8.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.63 |
| AVG Volume (30 Days) | 83.6K | ★ 5.7M |
| Earning Date | 01-01-0001 | 11-03-2025 |
| Dividend Yield | ★ 7.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $26,748,000.00 |
| Revenue This Year | N/A | $609.55 |
| Revenue Next Year | N/A | $197.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1137.19 |
| 52 Week Low | $14.36 | $1.54 |
| 52 Week High | $18.88 | $9.75 |
| Indicator | EOI | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 66.03 | 58.19 |
| Support Level | $20.40 | $8.04 |
| Resistance Level | $20.74 | $9.12 |
| Average True Range (ATR) | 0.21 | 0.45 |
| MACD | 0.07 | -0.18 |
| Stochastic Oscillator | 89.29 | 47.52 |
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation. The company's sector allocation includes: Information Technology, Communication Services, Financials, Consumer Discretionary, Healthcare, Industries, Consumer Staples, Energy, Real Estate, and Materials.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.